4月17日 - ** 生物技术公司Kura Oncology KURA.O股价盘前上涨3.5%至9.25美元
** 公司称早期数据显示其实验性药物darlifarnib加cabozantinib能缩小晚期肾癌患者的肿瘤
** 透明细胞肾细胞癌是最常见的肾癌形式
** 公司称44%的患者肿瘤缩小，94%的患者病情得到控制，这意味着癌症没有恶化
** 即使是之前对卡博替尼（cabozantinib）不再响应的患者，也能看到肿瘤缩小。
** 该药物组合在各种测试剂量下都是安全和可耐受的--KURA
** 研究已进入下一阶段，以观察 darlifarnib 是否有助于克服卡博替尼耐药性--公司
** 截至上次收盘，该公司股价今年下跌了约 14%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.